NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nektar Therapeutics (NKTR) Stock Analysis

Nektar Therapeutics (NKTR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NKTR

$74.19

−$2.18 (−2.85%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NKTR with… →

NKTR Key Statistics

As of Sep 4, 2026
Trading
Open
$74.67
Previous Close
$76.37
Day's Range
73.64–75.63
52-Week Range
33.40–109.00
Volume
607.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.15
Valuation
Market Cap
$2.53B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
46.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.94
Financials (FY)
Revenue (FY)
$55.23M−43.89%
Net Income (FY)
−$164.08M
Profit marginThe share of revenue left as profit after all costs and taxes.
−287.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.14M
1-Year Return
+106.20%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
852.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NKTR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+75.47%
2025+203.08%
2024+66.07%
2023−75.22%
2022−83.27%
2021−20.53%
2020−21.26%
2019−34.32%
2018−44.96%
2017+386.72%
2016 (partial year)−28.91%

As of September 4, 2026.

NKTR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$55.23M−$164.08M−297.1%
2024$98.43M−$118.96M−120.9%
2023$90.12M−$276.06M−306.3%
2022$92.06M−$368.20M−400.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$55.23M$55.23M−$130.77M−$164.08M−297.1%
2024$98.43M$67.74M−$129.92M−$118.96M−120.9%
2023$90.12M$56.35M−$135.23M−$276.06M−306.3%
2022$92.06M$70.42M−$240.24M−$368.20M−400.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NKTR Valuation vs Biotechnology Median

Median of 656 stocks
MetricNKTRBiotechnology medianvs median
P/S ratio46.4015.263.0x the median
Profit margin−287.84%0.00%287.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nektar Therapeutics (NKTR) at $2.53B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 63 employees.

The most recent close on file for NKTR is $74.19, dated September 4, 2026. That is −$2.18 (−2.85%) against the previous close. Over the past 52 weeks the price has ranged from $33.40 to $109.00. The latest close sits 122.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $55.23M. Against the prior fiscal year total of $98.43M, that is a change of −43.89%. The same year closed with a net loss of $164.08M. The reported profit margin is −287.84%. That is 287.8 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −5.94.

Across the 4 fiscal years on file, revenue moves from $92.06M in 2022 to $55.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.31. Measured against sales, the shares trade at 46.4 times revenue. On price-to-sales that is 3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.15. Annualized volatility over the trailing 10 years is 97.38%. Over the trailing twelve months the price has returned +106.20%. Across 10 years the annualized return works out at −12.34%.

Growth & Income

No dividend is on file for NKTR.

So far in 2026 the price is +75.47%. Across the complete calendar years on file, 2017 returned +386.72% and 2022 returned −83.27%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Nektar Therapeutics (NKTR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nektar Therapeutics NKTR $2.53B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nektar Therapeutics has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Visit website →